Colonial Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.3K Buy
29
+1
+4% +$681 ﹤0.01% 684
2026
Q1
$22K Sell
28
-4
-13% -$3.06K ﹤0.01% 665
2025
Q4
$24.4K Buy
32
+7
+28% +$4.75K ﹤0.01% 658
2025
Q3
$14.3K Sell
25
-3
-11% -$1.7K ﹤0.01% 708
2025
Q2
$14.5K Buy
28
+14
+100% +$7.81K ﹤0.01% 720
2025
Q1
$8.7K Sell
14
-7
-33% -$4.82K ﹤0.01% 774
2024
Q4
$14.7K Buy
21
+10
+91% +$8.39K ﹤0.01% 879
2024
Q3
$11K Buy
11
+2
+22% +$2.23K ﹤0.01% 789
2024
Q2
$9.53K Buy
9
+3
+50% +$2.91K ﹤0.01% 779
2024
Q1
$5.73K Buy
6
+2
+50% +$1.9K ﹤0.01% 811
2023
Q4
$3.66K Buy
+4
New +$3.29K ﹤0.01% 832

Other funds holding REGN

Colonial Trust's REGN Position: Q2 2026 in Review

Colonial Trust increased its Regeneron Pharmaceuticals (REGN) stake by 3.6% in Q2 2026, buying an estimated $681 and bringing the position to 29 shares worth $18.3K. The position accounts for ﹤0.01% of the portfolio, ranked #684.

Colonial Trust first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $24.4K in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Colonial Trust held 29 shares of Regeneron Pharmaceuticals worth $18.3K as of Q2 2026.
  • Colonial Trust bought 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $681.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Colonial Trust's portfolio in Q2 2026, its #684 holding.
  • Colonial Trust first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Colonial Trust's Regeneron Pharmaceuticals position peaked at $24.4K in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Colonial Trust's 13F filing for Q2 2026, filed 11 Aug 2026.